Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan Designations For Cancer Drugs: US FDA Urged To Distinguish Tissue-Agnostic From Tumor-Specific Diseases

Executive Summary

Generic and brand firms both seem to want ‘very black and white lines’ on orphan exclusivity, but FDA isn't so sure how to distinguish biomarker-targeted disease from histologically-defined disease.

You may also be interested in...



Checkpoint Inhibitors: US FDA Wants Consistent Adverse Event Definitions

Label writing is difficult because sponsors are collecting varying adverse reaction data, agency officials say.

Orphan, Combo, Pediatric Products Would See More Influence In Proposed US FDA Reorg

Reorganization also may force change to commissioner succession plan.

US FDA's Acting Orphan Products Development Director Has Gene Therapy Background

Ilan Irony will take over as acting director of the Office of Orphan Products Development later this month.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel